| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-74 |
Sentence |
denotes |
Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic. |
| T2 |
75-331 |
Sentence |
denotes |
Since the first description of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China in December 2019, it has evolved into a pandemic and emerged as an unprecedented worldwide crisis overwhelming healthcare systems globally. |
| T3 |
332-569 |
Sentence |
denotes |
Analysis of the available literature to date suggests that, in addition to older age, patients with underlying co-morbidities including hypertension, diabetes, heart disease are at higher risk for severe disease with increased mortality. |
| T4 |
570-816 |
Sentence |
denotes |
Practitioners around the world also have become increasingly concerned that immunosuppressed patients including those with autoimmune diseases may be at increased risk for developing Coronavirus Disease 2019 (COVID-19) with serious complications. |
| T5 |
817-996 |
Sentence |
denotes |
Very little is known about how anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis modifies the susceptibility, clinical presentation and disease course of COVID-19. |
| T6 |
997-1230 |
Sentence |
denotes |
In this review, we discuss the mechanism of action and challenges of the current therapeutic armamentarium of ANCA-associated vasculitis and outline approaches to management of ANCA-associated vasculitis during the COVID-19 pandemic. |
